S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Price, News & Analysis

$8.20
-0.14 (-1.68%)
(As of 03/28/2024 ET)
Today's Range
$8.16
$8.74
50-Day Range
$6.69
$11.00
52-Week Range
$6.20
$18.65
Volume
59,577 shs
Average Volume
121,881 shs
Market Capitalization
$145.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Nuvectis Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
156.1% Upside
$21.00 Price Target
Short Interest
Bearish
11.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$51,450 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.58) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

458th out of 939 stocks

Pharmaceutical Preparations Industry

222nd out of 444 stocks

NVCT stock logo

About Nuvectis Pharma Stock (NASDAQ:NVCT)

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

NVCT Stock Price History

NVCT Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Nuvectis Pharma Inc NVCT
Nuvectis Pharma GAAP EPS of -$0.37
Recap: Nuvectis Pharma Q3 Earnings
See More Headlines
Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NVCT
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+156.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.70 per share

Miscellaneous

Free Float
10,866,000
Market Cap
$145.71 million
Optionable
Not Optionable
Beta
0.34
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ron Bentsur M.B.A. (Age 58)
    Co-Founder, Chairman, CEO & President
    Comp: $851.61k
  • Dr. Enrique Poradosu Ph.D. (Age 57)
    Co-Founder, Executive VP, Chief Scientific & Business Officer
    Comp: $549.07k
  • Mr. Shay Shemesh (Age 40)
    Co-Founder, Executive VP, Chief Development & Operations Officer
    Comp: $529.27k
  • Mr. Michael Carson CPA (Age 47)
    Vice President of Finance

NVCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvectis Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVCT shares.
View NVCT analyst ratings
or view top-rated stocks.

What is Nuvectis Pharma's stock price target for 2024?

1 brokerages have issued 1-year price objectives for Nuvectis Pharma's stock. Their NVCT share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 156.1% from the stock's current price.
View analysts price targets for NVCT
or view top-rated stocks among Wall Street analysts.

How have NVCT shares performed in 2024?

Nuvectis Pharma's stock was trading at $8.34 on January 1st, 2024. Since then, NVCT stock has decreased by 1.7% and is now trading at $8.20.
View the best growth stocks for 2024 here
.

When is Nuvectis Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NVCT earnings forecast
.

How were Nuvectis Pharma's earnings last quarter?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.01.

When did Nuvectis Pharma IPO?

Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at $5.00-$7.00 per share.

Who are Nuvectis Pharma's major shareholders?

Nuvectis Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.70%), Vanguard Group Inc. (1.66%), Baldwin Brothers LLC MA (0.82%), Northern Trust Corp (0.36%), GSA Capital Partners LLP (0.16%) and Edmond DE Rothschild Holding S.A. (0.11%). Insiders that own company stock include Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur and Shay Shemesh.
View institutional ownership trends
.

How do I buy shares of Nuvectis Pharma?

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners